Hypomethylating agents in MDS and AML

Phase II IMpress study: imetelstat in patients with advanced MDS or AML failing HMA-based therapyПодробнее

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelod...Подробнее

The current guidelines and therapies for TP53-mutated MDS and AMLПодробнее

Dr. Scheinberg Highlights MDS, AML Abstracts at ASH 2023Подробнее

What are the hypomethylating agents currently being used to treat AML? #AMLПодробнее

What are the common side effects of hypomethylating agents #AMLПодробнее

Pevonedistat, azacitidine and venetoclax triplet therapy for AML, MDS and CMMLПодробнее

Higher-Risk Myelodysplastic Syndromes | Inside the Issue: Novel Agents, Approaches and Strategies...Подробнее

From MDS to AML: Genetics of Progression (featuring Prof Lars Bullinger)Подробнее

Can we do better than HMA in HR-MDS?Подробнее

The importance of targeting TP53 in AML and agents being exploredПодробнее

What are the broad categories of clinical trials currently underway for AML and MDS? #AMLПодробнее

Myelodysplastic Syndromes and Secondary AML– Update on Diagnosis and TreatmentПодробнее

Managing sAML from MDSПодробнее

What are hypomethylating agents? #AMLПодробнее

Transplant outcomes of AML/HR-MDS patients treated with sabatolimab plus HMAПодробнее

CPX-351 and gemtuzumab ozogamicin in R/R AML and MDSПодробнее

MDS - Myeloplastic Syndromes - 2023 Best of Hematology ConferenceПодробнее

Epigenetic mechanisms driving the progression of MDS to secondary AMLПодробнее

Precision Medicine in MDS and AMLПодробнее